Last reviewed · How we verify
VA-14
VA-14, marketed by The First Affiliated Hospital with Nanjing Medical University, is a small molecule drug with a specific mechanism of action targeting a particular bodily function. A key strength of VA-14 is its protected intellectual property, with the key composition patent expiring in 2028. The primary risk to VA-14 is the lack of detailed clinical trial results and revenue data, which may limit its market visibility and investor confidence.
At a glance
| Generic name | VA-14 |
|---|---|
| Sponsor | The First Affiliated Hospital with Nanjing Medical University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy (PHASE4)
- 7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy (PHASE4)
- High-Dose Dual Therapy for H. Pylori Eradication (RETRO-HP Study)
- Vonoprazan Hp Dual or Triple Eradication Regimes (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VA-14 CI brief — competitive landscape report
- VA-14 updates RSS · CI watch RSS
- The First Affiliated Hospital with Nanjing Medical University portfolio CI